J&J opens JLABs site in Canada

12 May 2016

US healthcare giant Johnson & Johnson (NYSE:JNJ) has opened a new life science incubator in Toronto, Canada, giving entrepreneurs access to facilities, funding and expertise to help them build early-stage companies and develop products.

While J&J and its European subsidiary Janssen have similar facilities in Europe and China, the Toronto site is the first of its JLABs to open outside of the USA.

The 40,000-square-foot life sciences incubator aims at providing entrepreneurs shared lab space and offices, modular lab suites and access to scientific, industry and capital funding experts. It can accommodate up to 50 start-ups and opens with 22 companies that represent a range of sectors, including therapeutics, medical devices and consumer health solutions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK